Table 2: Cytotoxicity and antiviral activity of derivatives 16c-26c against CV-B5 and Sb-1. Data represent mean values of three independent determinations. Pleconaril was used as a positive control.
| Compounds |
Vero76 |
CV-B5 |
Sb-1 |
| - |
aCC50 |
bEC50 |
- |
| 16c |
>100 |
53 |
>100 |
| 17c |
>100 |
6.9 |
20.5 |
| 18c |
>100 |
5.5 |
17.5 |
| 19c |
>100 |
>100 |
>100 |
| 20c |
87 |
>87 |
>87 |
| 21c |
>100 |
>100 |
>100 |
| 22c |
>100 |
>100 |
>100 |
| 23c |
>100 |
>100 |
>100 |
| 24c |
>100 |
>100 |
>100 |
| 25c |
>100 |
>100 |
>100 |
| 26c |
>100 |
>100 |
>100 |
| Ref. compds |
- |
- |
- |
| Pleconaril |
77±6.8 |
0.005±0.002 |
2±0.6 |
aCompound concentration (µM) required to reduce the viability of mock-infected Vero76 monolayers by 50%.
bCompound concentration (µM) required to reduce the plaque number of the indicated virus by 50% in Vero76 monolayers.